| Full Name | Euchromatic Histone Lysine Methyltransferase 2 |
|---|---|
| Symbol | EHMT2 (also G9a) |
| Chromosomal Location | 6p21.1 |
| NCBI Gene ID | [10993](https://www.ncbi.nlm.nih.gov/gene/10993) |
| OMIM | [618586](https://www.omim.org/entry/618586) |
| Ensembl ID | ENSG00000108799 |
| UniProt ID | [Q96KQ7](https://www.uniprot.org/uniprot/Q96KQ7) |
| Associated Diseases | Congenital disorder of glycosylation, neurodegeneration, intellectual disability |
EHMT2 (also known as G9a or KMT1C) is a histone lysine methyltransferase that catalyzes the mono- and dimethylation of histone H3 at lysine 9 (H3K9me1/2). It is a crucial epigenetic regulator involved in transcriptional repression, embryonic development, and cellular differentiation. EHMT2 forms a heterodimer with EHMT1 (GLP) and together they constitute the G9a/GLP complex, which is the primary H3K9 methyltransferase in mammalian cells.
In the central nervous system, EHMT2 plays critical roles in neuronal development, synaptic plasticity, and memory formation. Dysregulation of EHMT2 activity has been implicated in multiple neurodegenerative diseases, making it a potential therapeutic target.
EHMT2 (also known as G9a or KMT1C) is a histone lysine methyltransferase that catalyzes the mono- and dimethylation of histone H3 at lysine 9 (H3K9me1/2). It is a crucial epigenetic regulator involved in transcriptional repression, embryonic development, and cellular differentiation.
EHMT2/G9a is implicated in several neurodegenerative diseases:
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Amyotrophic Lateral Sclerosis (ALS)
G9a/EHMT2 inhibitors are being explored as therapeutic agents: